Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
EZH2 is a histone-lysine N-methyltransferase and the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2). It methylates lysine 27 on histone H3 (H3K27me), leading to transcriptional repression. It is involved in various cancers and plays a role in stem cell identity. EZH2 activity is regulated by post-translational modifications and antagonistic epigenetic marks. It primarily localizes to the nucleus. It can also methylate non-histone proteins.
EZH2 inhibition disrupts PRC2 complex function, leading to altered gene expression and cell death in susceptible cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone-lysine N-methyltransferase EZH2 (EZH2).